Cytosorbents Corporation
CTSO
$1.10
-$0.03-2.66%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 43.66% | 34.84% | -8.96% | 36.53% | -49.41% |
| Total Depreciation and Amortization | -3.96% | 0.74% | -44.09% | 71.36% | 1.14% |
| Total Amortization of Deferred Charges | 1,879.44% | -200.00% | -- | -- | -- |
| Total Other Non-Cash Items | -220.46% | -31.31% | 269.75% | -142.88% | 81,775.61% |
| Change in Net Operating Assets | 146.12% | -101.97% | -1,943.07% | -55.69% | 113.62% |
| Cash from Operations | 48.67% | 0.73% | 24.62% | -23.07% | 24.91% |
| Capital Expenditure | -733.52% | 59.73% | 52.67% | 32.94% | -168.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.29% | -24.21% | -102.48% | 64.96% | -66.62% |
| Cash from Investing | -148.87% | 5.59% | 6.55% | 47.26% | -283.68% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -600.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -99.56% | 1,783.46% | -30.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 92.71% | -- | -- | -- | -- |
| Cash from Financing | -101.01% | 1,819.94% | -104.68% | 1,783.46% | -30.37% |
| Foreign Exchange rate Adjustments | 222.06% | -1,303.45% | 105.88% | -526.84% | 166.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -157.18% | 187.82% | -199.18% | 216.19% | 18.73% |
